SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-009712
Filing Date
2022-05-12
Accepted
2022-05-12 16:32:10
Documents
51
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q labp-20220331.htm   iXBRL 10-Q 1376289
2 EX-31.1 labp-ex31_1.htm EX-31.1 26568
3 EX-31.2 labp-ex31_2.htm EX-31.2 24363
4 EX-32.1 labp-ex32_1.htm EX-32.1 15878
5 EX-32.2 labp-ex32_2.htm EX-32.2 15352
  Complete submission text file 0000950170-22-009712.txt   4927749

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT labp-20220331_def.xml EX-101.DEF 111853
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT labp-20220331.xsd EX-101.SCH 31069
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT labp-20220331_lab.xml EX-101.LAB 307383
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT labp-20220331_pre.xml EX-101.PRE 214463
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT labp-20220331_cal.xml EX-101.CAL 31803
45 EXTRACTED XBRL INSTANCE DOCUMENT labp-20220331_htm.xml XML 738249
Mailing Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060
Business Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060 540-818-2844
Landos Biopharma, Inc. (Filer) CIK: 0001785345 (see all company filings)

IRS No.: 815085535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39971 | Film No.: 22918390
SIC: 2834 Pharmaceutical Preparations